Challenges of implementing pharmacogenetics in the critical care environment

Nature Reviews Drug Discovery

Volumn 3, Issue 1, 2004, Pages 88-93

  Freeman, Bradley D ^a   McLeod, Howard L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE; DRUG METABOLIZING ENZYME; MUSCLE RELAXANT AGENT; PROCAINAMIDE; PROTON PUMP INHIBITOR; SUXAMETHONIUM; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; WARFARIN;

ALLELE; APNEA; ARTICLE; CANCER GENETICS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG ACTIVITY; DRUG METABOLISM; GENE SEQUENCE; GENE TECHNOLOGY; GENETIC RISK; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; HUMAN GENOME; IMMUNOPATHOGENESIS; INTENSIVE CARE; INTESTINE ISCHEMIA; MEDICAL CARE; OUTCOMES RESEARCH; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0347135822     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1285     Document Type: Article

References (89)

1. Bloomfield, E. L. The impact of economics on changing medical technology with reference to critical care medicine in the United States. Anesth. Analg. 96, 418-425 (2003).
2. Ball, S. & Borman, N. Pharmacogenetics and drug metabolism. Nature Biotechnol. 15, 925-927 (1997).
3. Linder, M. W., Prough, R. A. & Valdes, R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. 43, 254-266 (1997).
4. Nebert, D. W. Polymorphisms in drug-metabolizing enzymes: what is their relevance and why do they exist? Am. J. Hum. Genet. 60, 265-271 (1997).
5. Evans, W. E. & Reilling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
6. Weinshillboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
7. Kruglyak, L. & Nickerson, D. A. Variation is the spice of life. Nature Genet. 27, 234-236 (2001).
8. Evans, W. E. & McLead, H. L. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
9. Roses, A. D. Pharmacogenetics and future drug development and delivery. Lancet 355, 1358-1361 (2000).
10. Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000).
11. Nabel, E. G. Cardiovascular disease. N. Engl. J. Med. 349, 60-72 (2003).
12. Kalow, W. Pharmacogenetics in biological perspective. Pharmacol. Rev. 49, 369-379 (1997).
13. Lennard, L., Lilleyman, J. S., Van Loon, J. & Weinshillboum, R. M. Genetic variation in response to O-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 336, 225-299 (1990).
14. Black, A. J. et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716-718 (1998).
15. Aithal, G. P., Day, C. P., Kesteven, P. J. L. & Daly, A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding. Lancet 353, 717-719 (1999).
16. Higashi, M. K. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
17. Kalow, W. The ralation between dose of succinyl choline and duration of apnea in man. J. Pharmacol. Exp. Ther. 120, 203-214 (1957).
18. McGuire, M. C. et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. Natl Acad. Sci. USA 86, 953-957 (1989).
19. Roden, D. M. in The Pharmacological Basis of Therapeutics (eds Hardman, J. G. & Limbird, L. L.) 933-970 (McGraw-Hill, New York, 2001).
20. Hamdy, S. I. et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULTIA1, and MDR-1 in the Egyptian population. Br. J. Clin. Pharmacol. 55, 560-569 (2003).
21. Wang, H. E., O'Conner, R. E., Domeier, R. M. & National Association of EMS Physicians Standards and Clinical Practice Committee. Pre-hospital rapid sequence intubation. Prehosp. Emerg. Care 5, 40-48 (2001).
22. Taylor, P. in The Pharmacological Basis of Therapeutics (eds Hardman, J. G. & Limbird, L. L.) 192-214 (McGraw-Hill, New York, 2001).
23. Zoeller, J. Top 200 drugs. Am. Druggist 46-50 (1998).
24. Sullivan-Klose, T. H. et al. The role of CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996).
25. Takahashi, H. et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther. 63, 519-528 (1998).
26. Bhasker, C. R., Miners, J. O., Coulter, S. & Birkett, D. J. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7, 51-58 (1997).
27. Furuya, H. et al. Genetic polymorphisms of CYP2C29 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5, 389-392 (1995).
28. Steward, D. J. et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogentics 7, 361-367 (1997).
29. Tabrizi, A. R. et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receivings warfarin. J. Am. Coll. Surg. 194, 267-273 (2002).
30. Raschke, R. A., Reilly, B. M., Guidry, J. R. Fontana, J. R. & Srinivas, S. The weight-based heparin dosing nomogram compared with a standard care nomogram. Ann. Intern. Med. 119, 874-881 (1993).
31. Myers, W. C. & Chari, R. S. in Textbook of Surgery (eds Sabiston, D. C. & Lyerly, H. K.) 1046-1061 (W. B. Saunders, Philadelphia, 1997).
32. Perez, J. M. et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature Med. 9, 1300-1305 (2003).
33. 2c-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135-1142 (2002).
34. Natanson, c. et al. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J. Clin. Invest. 78, 259-270 (1986).
35. Parker, M. M., Shelhammer, J. H., Natanson, C., Alling, D. W. & Parrillo, J. E. Serial cardiovascular variables in survivors and non-survivors of human septic shock: heart rate as an early predictor of prognosis. Crit. Care Med. 15, 923-929 (1987).
36. 2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030-1035 (2001).
37. 2-adrenoreceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100, 3184-3188 (1997).
38. Siddiqui, A. et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348, 1442-1448 (2003).
39. Furuta, T. et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer disease. Ann. Inter. Med. 129, 1027-1039 (1998).
40. Angus, D. C. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 (2001).
41. Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003).
42. Marshall, J. C. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nature Rev. Drug Discov. 2, 391-405 (2003).
43. Natanson, C., Hoffman, W. D., Suffredini, A. F., Eichacker, P. Q. & Danner, R. L. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Med. 120, 771-783 (1994).
44. Zeni, F., Freeman, B. D. & Natanson, C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25, 1095-1100 (1997).
45. Freeman, B. D. & Natanson, C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin. Investig. Drugs 9, 1651-1663 (2000).
46. Tabrizi, R. T., Zehnbuer, B. A., Buchman, T. G. & Freeman, B. D. Genetic markers in sepsis. J. Am. Coll. Surg. 192, 106-117 (2001).
47. Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O. & Duff, G. O. Effects of a polymorphism in the human tumor necrosis factor-α promoter on transcriptional activity. Proc. Natl. Acad. Sci. USA 94, 3195-3199 (1997).
48. McGuire, W., Hill, A. V. S., Allsopp, C. E. M., Greenwood, B. M. & Kwiatkowski, D. Variation in the TNF promoter region associated with susceptibility to cerebral malaria. Nature 371, 508-511 (1994).
49. Nadel, S., Newport, M. J., Booy, R. & Levin, M. Variation in the tumor necrosis factor gene promoter region may be associated with death from meningococcal disease. J. Infect. Dis. 174, 878-880 (2000).
50. Stuber, F. et al. -308 Tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J. Inflamm, 46, 50 (1996).
51. Mira, J. P. et al. Association of TNF2, a TNF promoter polymorphism, with septic shock susceptibility and mortality - a multicenter study. JAMA 282, 561-568 (1999).
52. Tang, G. et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit. Care Med. 28, 2733-2736 (2000).
53. O'Keefe, G. E., Hybki, D. L. & Munford, R. S. The G→A single nucleotide polymorphism at the -308 position in the tumor necrosis factor-α promoter increases the risk for severe sepsis after trauma. J. Trauma 52, 817-826 (2002).
54. Majetschak, M. et al. Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma. Clin. Diagn. Lab. Immunol. 9, 1205-1211 (2002).
55. Gordon, A. C. et al. Lack of association between the -308 TNF promoter polymorphism and outcome from sepsis and septic shock. Intensive Care Med. 28 (Suppl. 1). S99 (2002).
56. Vieland, V. J. The replication requirement. Nature Genet. 29, 245 (2001).
57. Terwilliger, J. D., Haghighi, F., Hiekkalinna, T. S. & Goring, H. H. H. A biased assessment of the use of SNPs in human complex traits. Curr. Opin. Genet. Dev. 12, 726-734 (2002
58. Ioannidis, J. P. A., Trikalinos, T. A., Ntzani E. E. & Contopoulos-Ioannidis, D. G. Genetic association in large versus small studies: an empirical assessment. Lancet 361, 567-571 (2003).
59. Ioannidis, J. P. A., Ntzani E. E., Trikalinos, T. A. & Contopoulos-Ioannidis, D. G. Replicaiton validity of genetic association studies. Nature Genet 29, 306-309 (2001).
60. Terwillinger, J. D. Weiss K. M. Linkage disequilibrium mapping of complex disease: fantasy or reality? Curr. Opin. Biotechnol. 9, 578-594 (1998).
61. Calhoun, H. M., McKeigue, P. M. & Smith, G.D. Problems of reporting genetic associations with complex outcomes. Lancet 361, 865-872 (2003).
62. Attia, J., Thakkinstian, A. & D'Este, C. Meta-analysis of molecular association studies: methodologic lessons for genetic epidemiology. J. Clin. Epidemiol. 56, 297-303 (2003).
63. Holtzman, N. A. & Marteau, T. M. Will genetics revolutionize medice? N. Engl. J. Med. 343,141-144 (2002).
64. Rivers, E. et al. Early goal-directed therapy in the treatment of sepsis and septic shock. N. Engl. J. Med. 345, 1368-1377 (2001).
65. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 342, 1301-1308 (2000).
66. Van den Berghe, G. et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med. 345, 1359-1367 (2001).
67. Bogardus, S. T., Concata, J. & Feinstein, A. R. Clinical epidemiological quality in molecular genetic research - the need for methodological standards. JAMA 281, 1919-1926 (2003).
68. Peters, D. L., Barber, R. C., Flood, E. M., Garner, H. R. & O'Keefe, G. E. Methodological quality and genotyping reproducibility in studies of tumor necrosis factor -308 G→A single nucleotide polymorphism and bacterial sepsis: implications for studies of complex traits. Crit. Care Med. 31, 1691-1696 (2003).
69. Todd, J. A. Interpretation of results from genetic studies of multifactorial diseases. Lancet 354 (Suppl. 1), 15-16 (1999).
70. Cardon, L. R. & Abecasis, G. R. Using haplotype blocks to map human complex trait loci. Trends Genet. 19, 135-140 (2003).
71. Exner, D. V., Dries, D. L., Domanski, M. J. & Cohn, J. N. Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared with white patients with left ventricular dysfunction. N. Engl. J. Med. 344, 1351-1357 (2001).
72. Wood. A. J. J. Racial differences in response to drugs - pointers to genetic differences. N. Engl. J. Med. 344, 1393-1396 (2001).
73. Wilson, J. F. et al. Population genetic structure of variable drug response. Nature Genet 29, 265-269 (2001).
74. Noah, L. The coming pharmacogenomics revolution: Tailoring drugs to fit patients' genetics profiles. Jurimetrics 43, 1-28 (2002).
75. Rothstein, M. A. & Epps, P. G. Ethical and legal implications of pharmacogenetics. Nature Rev. Genet. 2, 228-231 (2001).
76. Karlawish, J. H. T. Research involving cognitively impaired adults. N. Engl. J. Med. 348, 1389-1392 (2003).
77. McRae, A. D. & Weijer, C. Lessons from everyday lives: a moral justification for acute care research. Crit. Care Med. 30, 1146-1151 (2002).
78. Rothstein, M. A. & Hornung, C. A. in Pharmacogenomics: Social, Ethical, and Clinical Dimensions (ed. Rothstein, M. A.) 3-27 (Wiley-Liss, Hoboken, 2003).
79. Kwok, P.-Y. High-throughput genotyping assay approaches. Pharmacogenomics 1, 95-100 (2000).
80. Freeman, B. D., Buchman, T. B., McGrath, S., Tabrizi, A. R. & Zehnbauer, B. Template-directed dye terminator incorporation with fluorescence polarization detection for analysis of single nucleotide polymorphisms associated with sepsis. J. Mol. Diagn. 4, 209-215 (2002).
81. Freeman, B. D., Buchman, T. G. & Zehnbauer, B. A. Template-directed dye-terminator incorporation with fluorescence polarization detection (TDI-FP) for analysis of single nucleotide polymorphisms (SNP) associated with cardiovascular and thromboembolic disease. Thromb. Res. (in the press).
82. Steemers, F. J. Ferguson, J. A. & Walt, D. R. Screening fiber-optic gene arrays. Nature Biotechnol. 18, 91-94 (2000).
83. Walt, D. R. Techview: molecular biology. Bead-based fiber-optic arrays. Science 287, 451-452 (2000).
84. Iglehart, J. K. The American health care system-expenditures. N. Engl. J. Med. 340, 70-76 (1999).
85. Eichacker, P. Q. et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies. Am. J. Respir. Crit. Care Med. 166, 1197-1205 (2002).
86. Minneci, P., Deans, K., Natanson, C. & Eichacker, P. Q. Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis. Eur. J. Clin. Microbial. Infect. Dis. 22, 1-9 (2003).
87. Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
88. Warren, H. S., Suffredini, A. F., Eichacker, P. Q. & Munford, R. S. Risk and benefits of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347, 1027-1030 (2002).
89. Siegel, J. P. Assessing the use of activated protein C in the treatment of severe sepsis. N. Engl. J. Med. 347, 1030-1034 (2002).